NK-92

NK-92 is a unique cell line derived from a patient with non-Hodgkin lymphoma. This cell line is of interest due to its natural killer (NK) cell properties, which include the ability to kill cancer cells and virus-infected cells without prior sensitization or recognition of specific antigens.

History

The NK-92 cell line was first established in 1992 by Hans Klingemann and his team. The cells were derived from a 50-year-old male patient with rapidly progressive non-Hodgkin lymphoma. Despite the aggressive nature of the disease, the patient's immune system had a high number of active NK cells, which were then used to create the NK-92 cell line.

Characteristics

NK-92 cells are unique in their ability to kill a wide range of cancer cells and virus-infected cells. They do not require prior sensitization or recognition of specific antigens, which sets them apart from other immune cells such as T cells and B cells.

NK-92 cells express several receptors that are involved in the recognition and killing of target cells. These include the natural cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46, as well as the killer cell immunoglobulin-like receptors (KIRs).

Clinical Applications

Due to their potent cytotoxic activity, NK-92 cells have been explored as a potential treatment for various types of cancer. They have been used in clinical trials for the treatment of melanoma, renal cell carcinoma, and lung cancer, among others.

In these trials, patients receive infusions of NK-92 cells, which then target and kill the cancer cells. Early results have been promising, with some patients showing significant reductions in tumor size and improved survival rates.

Future Directions

Research is ongoing to further understand the potential of NK-92 cells in cancer treatment. This includes studies to enhance their cytotoxic activity, improve their targeting of cancer cells, and reduce potential side effects.

NK-92 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia